CHOOSING AN APPROPRIATE THERAPY MATTERS

IN A CLINICAL STUDY, HAEGARDA REDUCED ATTACKS BY 95%^*

COMPACT PHASE 3 STUDY^1†

Chart showing 95% overall reduction in HAE attacks per month relative to placebo

^* Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

^† Clinical study for Optimal Management of Preventing Angioedema with low-volume subcutaneous C1-inhibitor replacement Therapy.

C1-INH=C1 inhibitor.
HAE=hereditary angioedema.

SECONDARY ENDPOINT

Rescue Medication Use Per Month Relative to Placebo¹

The WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema states that patients should have HAE rescue medication available at all times.²

^‡ Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA vs placebo.

EXPLORATORY ENDPOINT

Severity of HAE Attacks¹

9% of patients on HAEGARDA 60 IU/kg experienced a severe attack, compared to 69% on placebo¹
Attacks were graded by investigators based on the intensity of the most severe symptom

SEE OPEN-LABEL EXTENSION STUDY DESIGN

HAEGARDA PROVIDES ATTACK-FREE DAYS FOR THE LONG TERM

COMPACT OPEN-LABEL EXTENSION STUDY—SUBGROUP ANALYSIS

IN A POST-HOC ANALYSIS OF PATIENTS TREATED WITH HAEGARDA

This post-hoc analysis is the longest reported use of HAEGARDA to date³

^§In a subgroup analysis of 24 U.S. patients receiving 60 IU/kg of HAEGARDA eligible to continue the open-label extension study for ≥12 months.³

C1-INH is a World Allergy Organization–recommended first-line, long-term prophylaxis therapy option.²

In a clinical study, 40% of people on 60 IU/kg were attack free during the 16-week treatment period. In a long-term follow up study, similar responses were seen up to a maximum of 2.5 years.

Get your appropriate patients started on HAEGARDA

DOWNLOAD THE REFERRAL & QUICKSTART FORM

References: 1. Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. 2. Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities. World Allergy Organ J. 2026;19(4):101335. doi:10.1016/j.waojou.2026.101335. 3. Craig T, Feuersenger H, Pragst I, et al. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202-208.

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Visit medical affairs

HAEGARDA PIVOTAL STUDY DESIGN

The COMPACT^* Phase 3 Study aimed to evaluate the efficacy and safety of HAEGARDA in reducing the frequency of hereditary angioedema (HAE) attacks¹

32-week, multicenter, randomized, double-blind, placebo-controlled, crossover study

90 patients including adults and adolescents (≥12 years of age) with symptomatic type 1 or type 2 HAE

HAEGARDA 60 IU/kg, HAEGARDA 40 IU/kg, or placebo was administered twice weekly (every 3 or 4 days)

Baseline HAE attack frequency was a mean of 8.8 in the 3 months before screening for the 60-IU/kg group

* Clinical study for Optimal Management of Preventing Angioedema with low-volume subcutaneous C1-inhibitor replacement Therapy.

Reference: 1. Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140.

CHOOSING AN APPROPRIATE THERAPY MATTERS

IN A CLINICAL STUDY, HAEGARDA REDUCED ATTACKS BY 95%*